^
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
02/22/2024
Initiation :
04/18/2019
Primary completion :
04/30/2024
Completion :
04/30/2028
ALK • HLA-B • HLA-C
|
ALK positive
|
Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
Phase 2
Seagen Inc.
Active, not recruiting
Last update posted :
02/20/2024
Initiation :
11/12/2020
Primary completion :
09/30/2024
Completion :
09/30/2024
TNFRSF8
|
TNFRSF8 expression
|
doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous
Phase 1
City of Hope Medical Center
Completed
Last update posted :
02/20/2024
Initiation :
10/29/2012
Primary completion :
02/02/2024
Completion :
02/02/2024
HLA-DRB1
|
PD-1 expression
|
Promune (agatolimod)
Phase 2
City of Hope Medical Center
Active, not recruiting
Last update posted :
02/19/2024
Initiation :
05/25/2017
Primary completion :
07/16/2021
Completion :
12/21/2024
ALK • TNFRSF8
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous
Phase 2
Deepa Jagadeesh
Recruiting
Last update posted :
02/19/2024
Initiation :
06/17/2016
Primary completion :
06/15/2024
Completion :
06/15/2027
TNFRSF8
|
Adcetris (brentuximab vedotin)
Phase 1/2
Constellation Pharmaceuticals
Recruiting
Last update posted :
02/16/2024
Initiation :
09/18/2019
Primary completion :
12/31/2025
Completion :
03/01/2026
MSI • ARID1A • BAP1
|
MSI-H/dMMR • ARID1A mutation
|
irinotecan • tulmimetostat (CPI-0209)
Phase 2
Takeda
Recruiting
Last update posted :
02/16/2024
Initiation :
02/10/2023
Primary completion :
07/31/2025
Completion :
12/31/2027
ALK • TNFRSF8
|
ALK positive • TNFRSF8 expression • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone
Phase 1
Seagen Inc.
Recruiting
Last update posted :
02/13/2024
Initiation :
02/29/2024
Primary completion :
06/30/2027
Completion :
04/30/2030
ALK • TNFRSF8
|
TNFRSF8 expression
Phase 3
Acrotech Biopharma Inc.
Recruiting
Last update posted :
02/07/2024
Initiation :
10/04/2023
Primary completion :
07/01/2030
Completion :
11/01/2030
ALK • TNFRSF8 • UGT1A1
|
TNFRSF8 expression • UGT1A1*1*1
|
doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)
Phase N/A
Takeda
Active, not recruiting
Last update posted :
02/07/2024
Initiation :
02/28/2023
Primary completion :
12/30/2024
Completion :
12/30/2024
TNFRSF8
|
TNFRSF8 expression
Phase 1/2
City of Hope Medical Center
Active, not recruiting
Last update posted :
02/02/2024
Initiation :
02/04/2019
Primary completion :
06/29/2024
Completion :
06/29/2024
ALK
|
ALK positive • ALK negative
|
Keytruda (pembrolizumab) • Folotyn (pralatrexate)
Phase 2
Affimed GmbH
Completed
Last update posted :
02/02/2024
Initiation :
11/13/2019
Primary completion :
05/11/2022
Completion :
01/11/2024
TNFRSF8
|
TNFRSF8 positive
|
acimtamig (AFM13)
Phase 2
Solasia Pharma K.K.
Completed
Last update posted :
01/26/2024
Initiation :
03/25/2016
Primary completion :
10/11/2020
Completion :
06/17/2021
ALK
|
ALK positive
|
Zinapar (darinaparsin)
Phase N/A
Massachusetts General Hospital
Recruiting
Last update posted :
01/24/2024
Initiation :
01/01/2024
Primary completion :
01/01/2028
Completion :
01/01/2028
TNFRSF8
Phase 2
Affimed GmbH
Recruiting
Last update posted :
01/17/2024
Initiation :
10/10/2023
Primary completion :
04/30/2026
Completion :
11/30/2027
ALK • TNFRSF8
|
ALK positive • TNFRSF8 positive • ALK negative
|
cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (AB-101)
Phase N/A
Takeda
Completed
Last update posted :
01/15/2024
Initiation :
12/31/2019
Primary completion :
12/13/2023
Completion :
12/13/2023
TNFRSF8
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
Phase 3
University Medical Center Groningen
Not yet recruiting
Last update posted :
01/01/2024
Initiation :
01/01/2024
Primary completion :
01/01/2025
Completion :
01/01/2026
TNFRSF8
|
TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
Phase 1
SciTech Development, LLC
Recruiting
Last update posted :
12/25/2023
Initiation :
12/18/2023
Primary completion :
05/01/2025
Completion :
11/01/2025
TNFRSF8
|
TNFRSF8 expression
|
fenretinide nanoparticle (ST-001 nanoFenretinide)
Phase 2
Sethi
Recruiting
Last update posted :
12/20/2023
Initiation :
07/10/2023
Primary completion :
04/30/2028
Completion :
07/30/2028
TNFRSF8
|
Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Active, not recruiting
Last update posted :
12/19/2023
Initiation :
10/15/2018
Primary completion :
12/15/2023
Completion :
12/15/2028
TNFRSF8
|
TNFRSF8 expression • Albumin-L
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin)
Phase 1/2
University of Nebraska
Completed
Last update posted :
12/13/2023
Initiation :
09/28/2015
Primary completion :
11/01/2019
Completion :
11/01/2020
ALK
|
ALK positive • ALK negative
|
lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous
Phase 1/2
Henan Cancer Hospital
Recruiting
Last update posted :
12/13/2023
Initiation :
02/20/2022
Primary completion :
02/01/2024
Completion :
01/01/2027
ALK
|
ALK positive • ALK negative
|
Epidaza (chidamide) • parsaclisib (INCB50465)
Phase N/A
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
12/13/2023
Initiation :
07/27/2023
Primary completion :
07/27/2030
Completion :
07/27/2030
ALK • CD8
|
ALK positive • ALK negative
Phase 2
The Lymphoma Academic Research Organisation
Recruiting
Last update posted :
12/05/2023
Initiation :
10/05/2021
Primary completion :
01/30/2025
Completion :
01/30/2027
KIR3DL2
|
gemcitabine • lacutamab (IPH4102)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
11/29/2023
Initiation :
04/05/2023
Primary completion :
03/11/2024
Completion :
03/10/2025
ALK • BCL2
|
MYC rearrangement
|
Venclexta (venetoclax) • enitociclib (VIP152)
Phase 1/2
Sun Yat-sen University
Recruiting
Last update posted :
11/29/2023
Initiation :
08/15/2023
Primary completion :
08/01/2026
Completion :
12/01/2026
ALK • TNFRSF8
|
ALK positive • TNFRSF8 expression • ALK negative
|
Itari (linperlisib)
Phase 1
Shanghai General Hospital, Shanghai Jiao Tong U...
Recruiting
Last update posted :
11/28/2023
Initiation :
05/04/2022
Primary completion :
08/01/2024
Completion :
11/01/2024
CD7
Phase 1
Robert Lowsky
Completed
Last update posted :
11/22/2023
Initiation :
01/01/2012
Primary completion :
09/01/2016
Completion :
10/01/2016
CD8
Phase 2
UNC Lineberger Comprehensive Cancer Center
Recruiting
Last update posted :
11/18/2023
Initiation :
09/17/2019
Primary completion :
02/23/2028
Completion :
08/01/2038
TNFRSF8
|
TNFRSF8 expression
|
cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11
Phase N/A
Mayo Clinic
Recruiting
Last update posted :
11/13/2023
Initiation :
03/06/2013
Primary completion :
09/04/2024
Completion :
09/04/2024
CD20 • CCND1 • CD5 • FCER2 • VDR
|
Chr t(11;14)
Phase 1/2
Myeloid Therapeutics
Suspended
Last update posted :
11/13/2023
Initiation :
12/15/2021
Primary completion :
11/01/2024
Completion :
10/01/2025
ALK • CD5
|
ALK positive • ALK negative
|
cyclophosphamide • MT-101
Phase 2
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
11/01/2023
Initiation :
07/30/2021
Primary completion :
06/30/2025
Completion :
01/01/2026
PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME
|
TNFRSF8 expression • PD-1 expression
|
doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • Onureg (azacitidine oral)
Phase 2
University of Nebraska
Completed
Last update posted :
10/24/2023
Initiation :
12/08/2000
Primary completion :
12/30/2008
Completion :
12/30/2008
HLA-B
|
pentostatin • Leukine (sargramostim)
Phase 1
University of Alabama at Birmingham
Not yet recruiting
Last update posted :
10/19/2023
Initiation :
05/01/2024
Primary completion :
06/01/2028
Completion :
12/01/2029
CD4
|
Chr t(11;14) • CCND1 expression
|
Calquence (acalabrutinib) • Tazverik (tazemetostat)
Phase 2
City of Hope Medical Center
Completed
Last update posted :
10/19/2023
Initiation :
08/21/2018
Primary completion :
04/21/2021
Completion :
07/26/2023
BCL2
|
Venclexta (venetoclax) • Istodax (romidepsin)
Phase 1
Washington University School of Medicine
Recruiting
Last update posted :
10/12/2023
Initiation :
10/10/2023
Primary completion :
04/30/2026
Completion :
04/30/2026
CD7
|
CD7 expression
|
WU CART 007
Phase 1
Innate Pharma
Active, not recruiting
Last update posted :
10/11/2023
Initiation :
03/17/2022
Primary completion :
11/01/2023
Completion :
07/01/2024
KIR3DL2
|
lacutamab (IPH4102)
Phase 2
Northwestern University
Withdrawn
Last update posted :
10/10/2023
Initiation :
03/01/2020
Primary completion :
03/15/2026
Completion :
03/01/2029
TNFRSF8
|
TNFRSF8 positive • TNFRSF8 expression
|
Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
10/06/2023
Initiation :
07/18/2020
Primary completion :
04/15/2025
Completion :
04/15/2025
TNFRSF8
|
TNFRSF8 positive
|
cyclophosphamide • fludarabine IV • acimtamig (AFM13)